WO2022190016 - NOVEL DARPIN BASED MULTI-SPECIFIC T-CELL ENGAGERS
National phase entry:
Publication Number
WO/2022/190016
Publication Date
15.09.2022
International Application No.
PCT/IB2022/052126
International Filing Date
09.03.2022
Title **
[English]
NOVEL DARPIN BASED MULTI-SPECIFIC T-CELL ENGAGERS
[French]
NOUVEAUX AGENTS DE MISE EN CONTACT DE LYMPHOCYTES T MULTI-SPÉCIFIQUES À BASE DE DARPIN
Applicants **
MOLECULAR PARTNERS AG
Inventors
BIANCHI, Matteo
RESCHKE, Nina
GRIMM, Sebastian
REICHEN, Christian
SCHLERETH, Bernd
LEVITSKY, Victor
Priority Data
63/158,539
09.03.2021
US
63/172,973
09.04.2021
US
63/265,184
09.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6240 | |
| EPO | Filing, Examination, Granting | 86836 | |
| Japan | Filing, Examination, Granting | 4586 | |
| South Korea | Filing, Examination, Granting | 6702 | |
| USA | Filing, Examination, Granting | 26940 |
Total:
131,304
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets., such as, e.g, CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such mutt-specific proteins, pharmaceutical compositions comprising such proteins or nucleic- acids, and the use of such binding proteins, nucleic acids or pharmaceutical- compositions in methods for treating or diagnosing diseases, such as cancer, e.g.. acute myeloid leukaemia (AML), In a mammal, including a human.[French]
La présente invention concerne des protéines multi-spécifiques recombinées comprenant des agents de liaison présentant une spécificité de liaison pour différentes cibles, telles que, par exemple, CD3, CD33, CD123 et CD70. De plus, l'invention concerne des acides nucléiques codant de telles protéines spécifiques de mutt, des compositions pharmaceutiques comprenant de telles protéines ou de tels acides nucléiques, et l'utilisation de telles protéines de liaison, de tels acides nucléiques ou de telles compositions pharmaceutiques dans des méthodes de traitement ou de diagnostic de maladies, telles que le cancer, par exemple, la leucémie myéloïde aiguë (AML), chez un mammifère, notamment un être humain.